PaulEdwardSaxMD

PubMed

• Social Media Savvy, It's More Than Just the #Hashtags: How the Use of Social Media in Transplant Infectious Diseases Can Impact the Field and Patients.
  Courtney E Harris, Simran Gupta, Paul E Sax, Gabriel Vilchez, Ilan S Schwartz
  Transplant Infectious Disease. 2024-12-18
• 1 citations
  Management of Vulnerable Patients Hospitalized for COVID-19 With Remdesivir: A Retrospective Comparative Effectiveness Study of Mortality in US Hospitals.
  Essy Mozaffari, Aastha Chandak, Mark Berry, Paul E Sax, Paul Loubet
  Clinical Infectious Diseases. 2024-12-13
• 1 citations
  Remdesivir-Associated Survival Outcomes Among Immunocompromised Patients Hospitalized for COVID-19: Real-world Evidence From the Omicron-Dominant Era.
  Essy Mozaffari, Aastha Chandak, Robert L Gottlieb, Chidinma Chima-Melton, Mark Berry
  Clinical Infectious Diseases. 2024-12-13

Journal Articles

• Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Is Non-Inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive Adults with Human Immun...  
  George J Hanna, Peter Sklar, Kathleen E Squires, Paul E Sax, Carey Hwang, Clinical Infectious Diseases
• Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders  
  Walsh CE, Workowski K, Terrault NA, Sax PE, Cohen A, Bowlus CL, Kim AY, Hyland RH, Han B, Wang J, Stamm LM, Brainard DM, McHutchison JG, von Drygalski A, Rhame F, Frie..., Haemophilia, 1/25/2017
• Should we be testing for baseline integrase resistance in patients newly diagnosed with HIV?  
  Koullias Y, Sax PE, Fields NF, Walensky RP, Hyle EP, Clin Infect Dis, 1/12/2017
• Improving on effective antiretroviral therapy: how good will a cure have to be?  
  Freedberg KA, Sax PE, J Med Ethics, 1/1/2017
• Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial  
  Sax PE, DeJesus E, Crofoot G, Ward D, Benson P, Dretler R, Mills A, Brinson C, Peloquin J, Wei X, White K, Cheng A, Martin H, Quirk E, Lancet HIV, 1/1/2017
• Cardiovascular outcomes among HIV-infected veterans receiving atazanavir: a US national historical cohort study  
  Lafleur J, Bress AP, Rosenblatt L, Crook J, Sax PE, Myers J, Ritchings C, AIDS, 1/1/2017
• Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa  
  Paltiel AD, Zheng A, Weinstein MC, Gaynes MR, Wood R, Freedberg KA, Sax PE, Walensky RP, Open Forum Infect Dis, 1/1/2017
• Projecting 10-yr, 20-yr and Lifetime Risks of Cardiovascular Disease in Persons Living with HIV in the US  
  Losina E, Hyle EP, Borre ED, Linas BP, Sax PE, Weinstein MC, Rusu C, Ciaranello AL, Walensky RP, Freedberg KA, Clin Infect Dis, 1/1/2017
• Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study  
  Parker RA, Rabideau DJ, Sax PE, Tierney C, Daar ES, Collier AC, Losina E, Freedberg KA, Clin Infect Dis, 1/1/2017
• Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and M...  
  Borges AH, Lundh A, Tendal B, Bartlett JA, Clumeck N, Costagliola D, Daar ES, Echeverria P, Gisslen M, Huedo-Medina TB, Hughes MD, Huppler Hullsiek K, Khabo P, Komati ..., Clin Infect Dis, 1/15/2016
• Testing Limits  
  Massarotti EM, Sax PE, Compton L, Levy BD, Loscalzo J, N Engl J Med, 1/6/2016
• The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States  
  Girouard MP, Sax PE, Parker RA, Taiwo B, Freedberg KA, Gulick RM, Weinstein MC, Paltiel AD, Walensky RP, Clin Infect Dis, 1/1/2016
• Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and...  
  Wohl D, Oka S, Clumeck N, Clarke A, Brinson C, Stephens J, Tashima K, Arribas JR, Rashbaum B, Cheret A, Brunetta J, Mussini C, Tebas P, Sax PE, Cheng A, Zhong L, Calle..., J Acquir Immune Defic Syndr, 1/1/2016
• Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel  
  Gunthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, Hoy JF, Mugavero MJ, Sax PE, Thompson MA, Gandhi RT, Landovitz RJ, Smith DM, Jacobsen DM, Volberding PA, JAMA, 1/1/2016
• Short and long-term effects of telaprevir on kidney function in patients with hepatitis C virus infection: a retrospective cohort study  
  Sise ME, Backman ES, Wenger JB, Wood BR, Sax PE, Chung RT, Thadhani R, Kim AY, PLoS One, 1/29/2015
• Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: tw...  
  Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczer D, Molina JM, Oka S, Koenig E, Trottier B, Andrade-Villanueva J, Crofoot G, Custod..., Lancet, 1/27/2015
• Cost-effectiveness of genotype testing for primary resistance in Brazil  
  Luz PM, Morris BL, Grinsztejn B, Freedberg KA, Veloso VG, Walensky RP, Losina E, Nakamura YM, Girouard MP, Sax PE, Struchiner CJ, Paltiel AD, J Acquir Immune Defic Syndr, 1/1/2015
• The clinical role and cost-effectiveness of long-acting antiretroviral therapy  
  Ross EL, Weinstein MC, Schackman BR, Sax PE, Paltiel AD, Walensky RP, Freedberg KA, Losina E, Clin Infect Dis, 1/1/2015
• Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s  
  Longenecker CT, Kitch D, Sax PE, Daar ES, Tierney C, Gupta SK, McComsey GA; AIDS Clinical Trials Group Study A5224s Team, J Acquir Immune Defic Syndr, 1/1/2015
• Pink plaque on the arm of a man after a trip to Mexico: cutaneous leishmaniasis  
  Cohen JM, Saavedra AP, Sax PE, Lipworth AD, Dermatol Online J, 1/1/2015
• Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1  
  Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobo..., N Engl J Med, 1/1/2015
• Clinical problem-solving On the Nose  
  Abdalla M, Sax PE, Mostaghimi A, Miller AL, Loscalzo J, N Engl J Med, 1/1/2015
• Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US  
  Pei PP, Weinstein MC, Li XC, Hughes MD, Paltiel AD, Hou T, Parker RA, Gaynes MR, Sax PE, Freedberg KA, Schackman BR, Walensky RP, HIV Clin Trials, 1/1/2015
• Improving Influenza and Pneumococcal Vaccination Rates in Ambulatory Specialty Practices  
  Pennant KN, Costa JJ, Fuhlbrigge AL, Sax PE, Szent-Gyorgyi LE, Coblyn J, Desai SP, Open Forum Infect Dis, 1/1/2015
• Current state and limitations of daily oral therapy for treatment  
  Solomon DA, Sax PE, Curr Opin HIV AIDS, 1/1/2015
• Join now to see all

Books/Book Chapters

• Depression in Medical Illness 
  Chapter: Depression and Infectious Diseases 
  Grimaldi J, Harder J, Oser M, and Sax PEEditors: Barsky AJ and Silbersweig DA.McGraw-Hill, New York, NY2017
• HIV Essentials 
  Sax PE, Cohen CJ, and Kuritzkes DRJones and Bartlett PublishersEdition 7th,2014
• Principles and Practice of Hospital Medicine 
  Chapter: Approach to the Patient with HIV 
  Farel CF and Sax PEEditors: McKean SM, Ross JJ, Ginsberg J, Dressler D, Brotman D.McGraw-Hill, New York, NY2012
• Principles and Practice of Infectious Diseases 
  Chapter: Pulmonary Complications of HIV Infection 
  Page 1727 - 1736Sax PEEditors: Mandell GL, Bennett JE, and Dolin.Churchill Livingston2010
• Salvage Therapy, Current Opinion in HIV and AIDS 
  Page 459 - 550Editors: Katlama C, and Sax PE.2009
• Cecil Textbook of Medicine 
  Chapter: Immunopathogenesis of HIV Infection 
  Page 2137 - 2139Sax PE and Walker BDEditors: Goldman L and Ausiello D.W.B. SaundersEdition 23rd,2008
• Fishman's Pulmonary Diseases and Disorders 
  Chapter: Human immunodeficiency virus and pulmonary infection 
  Page 2241 - 2264Fangman J and Sax PEEditors: Fishman AP.McGraw Hill Medical2008
• Office Practice of Medicine 
  Chapter: Sexually Transmitted Diseases: Genital Lesions 
  Page 422 - 437Haynes HA and Sax PEEditors: Branch WT.W.B. Saunders, Branch WTEdition 4th,2003
• HIV 
  Chapter: Antiretroviral therapy 
  Page 77 - 100Hurtado RM and Sax PEEditors: Libman H and Makadon JH.American College of Physicians-American Society of Internal Medicine Press2003
• Pain Management, Anesthesia, and HIV/AIDS 
  Chapter: Clinical Manifestations of HIV Disease 
  Page 35 - 51Rodriguez W and Sax PEEditors: Nedeljkovic SS.Butterworth-Heinemann, Boston, MA2002
• Cunha's Antibiotic Essentials 
  Chapter: HIV Infection 
  Page 195 - 231Sax PEEditors: Cunha BA.Physicians' Press, Birmingham, MI2001
• Join now to see all

Lectures

• Review of Conference on Retroviruses and Opportunistic Infections 
  1/1/2017
• Treatment Update from International AIDS Society Meeting 
  1/1/2017
• Update from the Conference on Retroviruses and Opportunistic Infections 
  1/1/2017
• New and Investigational HIV Therapies 
  1/1/2017
• Combining Clinical Care and Research 
  1/1/2016
• Treatment of HCV: Big Sticks, Big Stickers 
  1/1/2016
• HIV and HCV Drug Development 
  1/1/2016
• Can I Ask You a Quick Question? 
  1/1/2016
• Stopping HIV: Advances in HIV Prevention 
  1/1/2016
• Meet the Professor: My Most Challenging HIV Cases 
  1/1/2016
• HIV Update for the Non-ID Clinician 
  1/1/2016
• Seeing the Whole Picture 
  1/1/2016
• Review of the Conference on Retroviruses and Opportunistic Infections 
  1/1/2015
• Antiretroviral Therapy Update 
  1/1/2015
• Challenging Cases in Antiretroviral Therapy: Focus on Drug Resistance 
  1/1/2015
• HIV Treatmen: Update from Vancouver and Resident’s Report 
  1/1/2015
• What is the Optimal Regimen for First Line Therapy? 
  1/1/2015
• Case of the Month: A 57 Year-Old Woman with 3 Months of Fever 
  1/1/2014
• Curing HCV: What Price Progress? 
  1/1/2014
• The Top HIV Studies of the Year 
  1/1/2014
• New and Emerging Therapies for HIV 
  1/1/2014
• HIV Drugs in the Pipeline 
  1/1/2014
• Update on HIV for the Non-ID Specialist 
  1/1/2014
• Summary of the 20th International AIDS Conference 
  1/1/2014
• Acute HIV Infection 
  1/1/2014
• Join now to see all

Other

• ClinicalQuiz™: So You Think You’re an HIV Expert 
  Sax PE, Daar ES, Eron JJ, Gallant JE, Hodder S, and Powderly WG, Clinical Care Options
  http://www.clinicaloptions.com/HIV/Treatment%20Updates/HIV%20Quiz/Module/Module_1.asp
  1/1/2013
• Answering the Questions: Initiating Antiretroviral Therapy 
  Sax PE, Clinical Care Options
  1/9/2009
• Key Principles and Recommended Regimens for First-Line Antiretroviral Therapy 
  Sax PE, Clinical Care Options InPractice
  http://www.clinicaloptions.com/inPractice.aspx
  1/1/2009
• Evolving Insights into the Optimal Timing of Antiretroviral Therapy 
  Sax PE
  1/23/2008
• Activity of NNRTI-Based Regimens in Patients with NRTI Resistance Mutations 
  Sax PE, Clinical Care Options
  1/27/2007
• Is There a Clinical Role for Lopinavir/Ritonavir Plus Efavirenz? Expert Commentary on Fischl MA, et al, AIDS. 2007 
  Sax PE, Clinical Care Options
  1/14/2007
• The Resistance Consequences of Virologic Failure on a Boosted PI Regimen 
  Sax PE, Clinical Care Options
  1/13/2007
• Treatment Options for an HIV-Infected Patient with Highly Drug–Resistant Virus 
  Sax PE, Clinical Care Options
  1/13/2007
• Case Challenge: Treatment Considerations in an HIV-Infected Patient with Ongoing Methamphetamine Use 
  Sax PE, Clinical Care Options
  1/12/2007
• Antiretroviral Selection in Treatment-Naive Patients 
  Sax PE, Clinical Care Options
  1/4/2007
• Safety and Tolerability of Recommended Regimens for First-Line Therapy 
  Sax PE, Clinical Care Options
  1/4/2007
• Conference Summaries of the Conference on Retroviruses and Opportunistic Infections, the Interscience Conference on Antimicrobial Agents and Chemotherapy, and the Inte... 
  Sax PE
  1/1/2007
• Avoiding and Managing Drug Resistance in HIV-Infected Patients 
  Sax PE, Clinical Care Options
  1/1/2007
• Options for First-Line Antiretroviral Therapy 
  Sax PE, Medscape Infectious Diseases
  1/1/2007
• Expanding HIV/AIDS Control: Incorporating the New DHHS and IAS-USA Guidelines in Practice 
  Sax PE, Medscape Infectious Diseases
  1/1/2007
• Emerging Antiretroviral Strategies and Therapeutic Options for Highly Treatment-Experienced Patients With HIV 
  Sax PE and Daar E, Medscape
  1/20/2006
• NNRTIs in Clinical Practice: Management of Adverse Effects in a Woman Switching From Fixed-Dose NRTIs to a DHHS-Recommended Regimen 
  Sax PE, Clinical Care Options
  1/19/2006
• Selecting a First-Line Regimen: Balancing Efficacy and Resistance Considerations 
  Sax PE, Clinical Care Options
  1/15/2006
• Choosing an Initial PI for PI-Naive Patients: Considerations When Selecting First-Line and Second-Line PI and Management of a Patient With Virologic Failure on His Ini... 
  Sax PE, Clinical Care Options
  1/13/2006
• Virologic Failure With M184V: What Is the Next Optimal NRTI Combination? 
  Sax PE, Clinical Care Options
  1/12/2006
• Understanding Trial Design Decisions in INITIO. Expert Commentary on Yeni P, et al, Lancet 2006 
  Sax PE, Clinical Care Options
  1/8/2006
• Fine-Tuning Antiretroviral Therapy in HIV-Infected Patients with Virologic Suppression: Strategies to Address Toxicity, Convenience, and Quality of Life 
  Sax PE
  1/6/2006
• Evaluating Fosamprenavir/Ritonavir as a First-Line Regimen. Expert Commentary on Eron J, et al, Lancet 2006 
  Sax PE, Clinical Care Options
  1/5/2006
• Understanding HIV Drug Resistance Testing: When to Test, How to Interpret 
  Sax PE, Clinical Care Options
  1/1/2006
• HIV Infection for the Primary Care Provider 
  Libman H and Sax PE, Online Continuing Medical Education Course
  http://cmeonline.med.harvard.edu
  1/1/2006
• Join now to see all